By Joseph Arcangelo, inSeption Group
Many contract research organizations (CROs) tout multitherapeutic capability, claiming they offer clients flexibility and accessibility to vast resources. However, multitherapeutic capability does not always provide the value a sponsor requires. In select instances, a CRO offering multitherapeutic services absolutely is the appropriate partner to run a clinical trial. In some cases, though, partnering with a multitherapeutic CRO can cost a sponsor time, money, and data quality — not to mention frustration and outright aggravation.